Please assess the completion status of the following clinical trial:

Trial Title: Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults (18 - 75) with a nasal swab confirmed SARS-CoV-2 infection; testing positive within 4 days of enrollment~2. Ability to read, understand and provide informed consent (no legally authorized representatives may consent on their behalf) and study assessments in English~3. Ability for subject to comply with the requirements of the study (must/will have a valid email address, internet connection and phone number)~4. Willingness to self limit medications and supplements and report what they are taking~5. Comfortable self-administering oral medication and nasal swab sampling~6. Willingness to permit a review of their medical history and to provide medical data from their electronic medical record for the period of enrollment (14 days) and until resolution of Covid-19 related events. Individuals who are not current Swedish patients will be asked to identify their provider of record and provide access to specific elements of their electronic health record.~7. Reside within twenty-five miles of one of the Swedish campuses: First Hill, Ballard, Edmonds, Issaquah, Cherry Hill.~Exclusion Criteria:~1. Reported history or evidence of impaired liver or kidney function: GFR \<30 or bilirubin \>2x ULT or INR \> 2x ULT in the absence of anticoagulants~2. Known hypersensitivity to zinc or resveratrol~3. Diagnosis of COVID-19 or SARS-CoV-2 infection \>4 days before enrollment~4. Preexisting severe pulmonary disease requiring supplemental oxygen~5. Clinically evident impairment of cognitive function, per physician discretion~6. Active substance abuse that may prevent the subject from completing the protocol requirements, per physician discretion.~7. Active psychotic or affective disorder that may prevent the subject from completing the protocol requirements, per physician discretion.~8. Pregnant or lactating females.~9. Coumadin treatment that can not be halted during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Resveratrol and Zinc Picolinate combination therapy (Type: ACTIVE_COMPARATOR): Resveratrol and Zinc Picolinate combination therapy
- Resveratrol Placebo and Zinc Placebo combination therapy (Type: PLACEBO_COMPARATOR): Placebo Resveratrol and Placebo Zinc combination therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).